OncLive® On Air

In today’s episode, we highlighted an OncLive Peer Exchange discussion about cancer-associated Lambert-Eaton myasthenic syndrome (LEMS) moderated by Misty D. Shields, MD, PhD. Dr Shields is an assistant professor of clinical medicine in the Department of Medicine in the Division of Hematology/Oncology at the Indiana University (IU) School of Medicine, as well as an adjunct assistant professor of medical & molecular genetics and an associate member of Experimental and Developmental Therapeutics at the IU Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis. She was joined by Triparna Sen, MD, PhD, MS, a professor at The Ohio State University in Columbus, and Ditte Primdahl, MD, an assistant professor of neurology (neuro-oncology) and neurological surgery at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
In this exclusive conversation, the experts discussed the ties between cancer-associated LEMS and small cell lung cancer. They noted that LEMS is characterized by proximal muscle weakness, hyperreflexia, and autonomic dysfunction, and that diagnostic challenges include late referral to neurology and misattribution of symptoms to cancer-related fatigue. They also highlighted key symptoms, which include proximal leg weakness, dry mouth, and blurred vision. Furthermore, they dove into treatment options for symptom control and emphasized that a multidisciplinary approach to care, including oncology, neurology, and laboratory medicine, is crucial for early LEMS diagnosis and effective management.

In today’s episode, we welcomed Everett Meyer, MD, PhD, an associate professor of medicine (blood & marrow transplantation), an associate professor of pediatrics (stem cell transplantation), and an associate professor of surgery (abdominal transplantation) at Stanford Medicine in California.
In the exclusive interview, Dr Meyer discussed the significance of the June 2026 FDA approval of allogeneic regulatory T cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi; Orca-T) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution, and to improve chronic graft-vs-host disease (cGHVD)–free survival in the treatment of adults with hematological malignancies. 
Dr Meyer also broke down what the approval of Orca-T means for the transplant field, detailed the design and key outcomes from the phase 3 Precision-T trial (NCT05316701) that supported the approval, and outlined how this approach could be integrated into clinical practice.

In today’s episode, we spoke with Paolo Tarantino, MD, PhD. Dr Tarantino is a breast medical oncologist and advanced fellow at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts.
In our exclusive interview, Dr Tarantino discussed practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting, including the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta) for first-line treatment of HER2-positive breast cancer based on findings from the phase 3 DESTINY-Breast09 trial (NCT04784715); updated safety data from the phase 3 DESTINY-Breast05 trial (NCT04622319) that indicated that T-DXd–associated interstitial lung disease is reversible with steroids, although radiation pneumonitis is non-reversible; and the phase 3 OPTIMA trial (ISRCTN42400492) results, which suggested that the PAM50 signature can identify patients who may not need chemotherapy, potentially sparing them from unnecessary treatment.

In today’s episode, we spoke with Sara M. Tolaney, MD, MPH, about the FDA approval of sacituzumab govitecan plus pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA-authorized test. Dr Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers and a senior physician at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School in Boston, Massachusetts.
This regulatory decision was backed by findings from the phase 3 ASCENT-04/KEYNOTE-D19 trial (NCT05382286), in which the median progression-free survival among patients in the sacituzumab govitecan arm was 11.2 months (95% CI, 9.3-16.7) vs 7.8 months (95% CI, 7.3-9.3) among patients who received physician’s choice of chemotherapy plus pembrolizumab (HR, 0.65; 95% CI, 0.51-0.84; P = .0009).
In our exclusive interview, Dr Tolaney highlighted the significance of this approval, key data from ASCENT-04, and how the TNBC paradigm is shifting to accommodate this new regimen.

In today’s episode, we spoke with Jorge E. Cortes, MD, and Elias Jabbour, MD. Dr Cortes is the chief of Hematology in the Division of Hematology and Oncology and the associate director for Translation at the UAB O’Neal Cancer Center in Birmingham, Alabama. Dr Jabbour is a professor of leukemia in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Dr Cortes and Dr Jabbour discussed the orally disintegrating tablet formulation of nilotinib (Cavhanza) and its recent June 2026 FDA approval for patients with chronic myeloid leukemia (CML). After diving into the approval itself and the data that supported it, they both discussed why the approval is significant and which patients it will benefit most. In addition to covering the approval, the two also shed light on what is to come for biosimilars and alternate formulations in the greater CML treatment paradigm.